Beyond Air, Inc. (NASDAQ:XAIR – Free Report) – Equities research analysts at Roth Capital increased their FY2025 earnings per share estimates for shares of Beyond Air in a research report issued to clients and investors on Tuesday, February 11th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.85) per share for the year, up from their prior estimate of ($1.01). The consensus estimate for Beyond Air’s current full-year earnings is ($0.87) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.02) EPS.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same quarter in the prior year, the firm earned ($0.50) earnings per share.
Beyond Air Trading Up 0.5 %
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in XAIR. Soros Fund Management LLC acquired a new stake in Beyond Air in the 3rd quarter valued at $573,000. Baldwin Wealth Partners LLC MA raised its holdings in Beyond Air by 721.3% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock worth $110,000 after acquiring an additional 270,500 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Beyond Air by 81.0% during the fourth quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock valued at $202,000 after purchasing an additional 251,823 shares during the last quarter. Institutional investors and hedge funds own 31.50% of the company’s stock.
Beyond Air Company Profile
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
See Also
- Five stocks we like better than Beyond Air
- What is the S&P 500 and How It is Distinct from Other Indexes
- Cisco Roars Back: Is the Tech Giant Reborn?
- Using the MarketBeat Dividend Tax Calculator
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
- How to Calculate Return on Investment (ROI)
- Forget Tesla: 3 Stocks to Ride the Elon Musk Effect
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.